Alexandria Real Estate Equities, Inc. (ARE)

Total return at 5 years: 22.9%/year = 18.0% appreciation + 4.9% dividend. The target price ($101) is ex-dividend; the $14 in dividends collected over 5 years are added separately.

By both methods, the value today (DCF $75 · Multiples $94) exceeds the market price ($44).

Today — with margin of safety: at $44 trades ~52.9% below its value discounted to today (~$94) — the wide discount we require (≥38%, equivalent to a ~15% annual return); the risk is covered by the margin, not the rate.

At 5 years — Muy infravalorado: the target price ($101) plus dividends yield above the required average return (10%) — the business compounds.

The bridge: the return at 5 years comfortably exceeds the risk-free rate (4.5%) — and the discount reaches the required margin of safety.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($44) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The market discounts less growth (-9.2%/year) than we project (2.0%/year) → if the base case holds, there is margin: perception is more pessimistic than the estimated reality.

That growth implies ~$0.3 bn of owner earnings in year 5 (vs ~$0.6 bn of our base case). It recalculates if the DCF assumptions are edited.

A REIT is valued on price/Core-FFO (not P/E: the accounting depreciation of the property is not an economic cost). ⚠️ The real cash is AFFO (owner earnings), substantially lower than Core FFO —it subtracts recurring capex and non-cash straight-line rent—, and the dividend consumes almost all of the AFFO. It returns capital via dividend; it may issue equity to fund development. Total return adds the dividend collected along the way. In edit mode, the metric, shares, dividend, and exit multiple can be adjusted.

Year 0 (TTM to Jun-2026) interpolates between the real FY2025 adjusted FFO per share (US$9.01) and FY2026 guidance (midpoint US$6.40, release of 3-Aug-2026), because the TTM window covers half of each period — both anchors are read from the filing/release, the headline is not extrapolated. Year +1 starts from the midpoint of current guidance (§5 R1 prior): -16.9% versus the TTM. The model assumes a trough toward 2026-2027 (occupancy still falling toward the guided range of 86.2%-87.8% for the end of 2026, leverage above target) and a gradual recovery from year 3 conditional on the US$2.9bn disposition program being completed and the laboratory oversupply being absorbed — a declared trough and recovery (the R1 bis exception), not a monotonic deceleration. The exit multiple starts from the floor of the method's REIT band (15×) only in year 5, with a partial normalization (13×) in year 3, because today the market pays a multiple far below the band on adjusted FFO (US$7.70 of TTM) — and the re-rating depends on the operation stabilizing, so it is not assumed complete from year 1. The share count is approximately stable across all three paths: no buybacks or material dilution are modeled.

Today's multiple compresses on its own going forward as the metric per share grows. The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—. Total return adds the dividend collected; the required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $101 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $44, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $101 in 5 years plus $14 of dividends collected (the dividend adds to the return, not to the price) and a required return of 4.5% annually, the maximum to pay today is $94. Against the current market price ($44), the margin of safety is 52.9% (trades below the maximum → there is margin) and the total return at that price would be 22.9% annually.

• Multiple versus method's band. Trades at ~6× adjusted FFO, well below the reference REIT band (15-20×) — the market is already discounting a real crisis, not just perception.
• Growth versus multiple. Base case assumes partial multiple normalization toward the band floor (15×) only by year 5, contingent on deleveraging and occupancy stabilization execution.
• Margin of safety. Base return (+23%) comfortably exceeds the 15% annual bar, but rests on operational recovery and multiple re-rating that have not yet occurred — the margin of safety requires that the adverse scenario not materialize.

Each margin over sales, year by year: historical (solid line) → projection (dotted).

• ✕ ROIC exceeds the cost of capital (~10%)
• ✓ CFROIC backs up the ROIC (252%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• Balance sheet quality. Leverage 7.0× net debt/adjusted EBITDA, above target (5.6-6.2×), though with 95.7% of debt fixed-rate and 9.7-year average life — the longest among S&P 500 REITs.
• Tenant quality. 53% of annual rent comes from investment-grade or large-cap public tenants — reduces portfolio credit risk even in weak occupancy.
• Cash quality (FFO versus impairments). Adjusted FFO excludes the US$2.20bn in impairments recognized in 2025, but that impairment signals that part of book value is already lost — not all accounting noise.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

The engine of a life sciences REIT is occupancy at rent rates on the Megacampus portfolio, plus development of new pre-leased projects. Today all three engines are moving against: occupancy is falling, renewal rents are declining, and leverage has risen above target — the thesis depends on the disposition program and occupancy stabilization reversing this mix from 2027-2028 onward.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (30-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Real, not nominal. Revenue and FFO decline is real (occupancy and rents falling), not a monetary or FX effect.
• Growth driver. Today the driver is negative (occupancy and rents declining); the model assumes deleveraging and oversupply absorption reverse it from 2028-2030.
• Sustainability. Depends on variables outside the company's direct control (biotech funding, interest rates, laboratory oversupply absorption) — not self-sustained growth driven by its own moat in the near term.

• Relevant in 10 years (recurrence). Specialized laboratory space is structural to the life sciences industry, but current oversupply shows demand did not grow at the rate the sector built during the post-pandemic boom.
• Pricing power. Eroded in the near term: 2026 guidance projects renewal rents declining -9% to -1% (GAAP) and -15% to -7% (cash basis) — the opposite of a business with intact pricing power.
• Moat and its direction. Megacampus locations difficult to replicate and long-term triple-net contracts, but eroding: laboratory availability in the three principal markets rose from ~4% (2021) to ~29% (today).
• Cyclicality / sensitivity. Highly sensitive to the biotech funding cycle (venture capital, research grants) and interest rates — both factors are pressuring simultaneously today.

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• !Credit quality (unencumbered + fixed rate)96% fixed rate · liquidity $3.6 bn
• ✕Portfolio quality (occupancy + same-store NOI)Occupancy 86.9% · same-store NOI +-8.6%
• !Dividend coverage (payout over AFFO)94% of AFFO

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Leverage above target. Net debt and preferreds to adjusted EBITDA at 7.0× (2Q26) versus 5.6-6.2× target by end of 2026 — achievement depends on the US$2.9bn disposition program.
• Conservative debt structure. 95.7% of debt fixed-rate, 9.7-year average life (longest among S&P 500 REITs) and US$3.6bn liquidity — buffers near-term refinancing risk.
• Fixed-charge coverage. Fixed-charge coverage ratio 3.3× (2Q26 annualized), down from 3.7× at end of 2025 but still with reasonable headroom.
• Dividend cushion post-cut. Payout as a percentage of adjusted FFO fell to ~33-42% post-cut — leaves cushion, but at the cost of breaking the dividend growth history.

How cash comes in and how it is deployed. In green, the business's own cash (the owner-FCF it generates and reinvests); in gray, the float and credit — customer and funding money, which is not the shareholder's.

Prioritizes deleveraging (5.6-6.2× target by end of 2026) financed by the US$2.9bn disposition program, and disciplined construction (~US$1.75bn guided for 2026, only high-preleased projects) over dividend growth or buyback, which is paused today ('opportunistic' per stated plan, with no execution in the LTM).

Who owns the shares — the alignment and whether there is a controlling shareholder.

• Skin in the game. No single controlling shareholder; the director and executive group holds ~5% of shares. Joel Marcus, founder, remains as Executive Chairman after more than three decades leading.
• Capital allocation. Prioritizes deleveraging (5.6-6.2× target by end of 2026) and disciplined construction (only high-preleased projects) over dividend growth or buyback, which is paused today.
• Integrity / candor. Management cut the dividend 45% and reduced 2026 FFO guidance acknowledging market deterioration, rather than sustaining an optimistic narrative — a genuine signal of candor.

• Genuine forced sellers: the 45% dividend cut and -29% FFO guidance cut for 2026 triggered an exodus of income-oriented investors who do not tolerate a cut dividend, independent of the remaining intrinsic portfolio value.
• Bottom of the sector cycle: laboratory availability in the principal clusters reached ~29% from ~4% in 2021 — a classic oversupply cycle (capital entered in excess during the post-pandemic biotech funding boom, and now compresses returns until demand absorbs the excess) that hammers the entire sector, not merely ARE's execution.
• But there is also a less benign forced seller signal: the US$2.20bn in real estate impairment in 2025 confirms that part of the decline reflects real value loss, not just panic — this thesis's safety margin depends on the rest of the portfolio (Megacampus, 80% of rent) avoiding the fate of already-impaired assets.

This is not a clean non-broken-business case: there are missing buyers (the dividend cut spooked income funds) but also real evidence of impairment (the US$2.20bn recognized, occupancy declining three consecutive periods). Current price (~6× adjusted FFO, well below the normal REIT band of 15-20×) requires that the guided deleveraging and occupancy stabilization be achieved; if not, the market's discount is justified and no real margin of safety exists.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at +10%/year (+60% total): the margin of safety protects the downside. The bull (+32%/year, +299% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Structural laboratory oversupply. Availability in the three principal markets rose from ~4% (2021) to ~29% (today); absorption may take years, and the model base already assumes slow recovery.
• Leverage and deleveraging execution. The 5.6-6.2× target depends on selling US$2.9bn in assets in a still-weak transaction market for laboratory real estate.
• Further real estate impairments. The US$2.20bn recognized in 2025 may not be the last if occupancy fails to stabilize in the guided range.
• R&D funding dependence. Tenant rent-payment capacity depends on venture capital and federal research funding (NIH, FDA) — both under pressure.
• Risk of a further dividend cut. The dividend is already cut 45% in 4Q25; further FFO deterioration could force another adjustment.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  Fails the quality gate: narrow moat, eroding.

• Peter Lynch Growth at a reasonable price (GARP)

  A slow grower growing 2% at a multiple/growth of 2.9 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Not applicable — the Magic Formula excludes financials and regulated businesses (EBIT/EV does not capture the operating leverage).

• Howard Marks Perception vs reality + cycle

  The price discounts -9% vs our 2%: perception is more pessimistic than reality, with an identified source of the discount.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor +4%/yr, bull-scenario ceiling +28%/yr over 5y and a +53% margin → capital protected, asymmetry in your favor.

• Pat Dorsey Moat strength (Five Rules)

  A narrow moat, eroding; sources: intangibles, efficient scale, switching costs, network effects → fails the Five Rules.

• Aswath Damodaran Expectations implied by the price

  Justifying the price requires discounting -9%, within what we project (2%) — the story squares with the numbers.